New application of Pulsatilloside A

Abstract

The invention provides an application of Pulsatiloside A in preparation of a medicine with an anti-radiation effect. Compared with other anti-radiation drugs, the Pulsatabiloside A disclosed by the invention is small in toxicity and good in anti-radiation effect.

Description

Technical Field

[0001] The present invention relates to a novel use of Pulsatilloside A. Summary of the invention

[0002] Pulsatilloside A (PSA) (CAS: 136684-41-8) is a triterpenoid saponin compound extracted from the plant genus Pulsatilla. The genus Pulsatilla contains about 40 species of perennial herbs, mainly distributed in grasslands and steppes in North America, Europe and Asia. In China, Pulsatilla decoction has been used to treat diseases caused by bacteria for thousands of years, among which Pulsatilla chinensis (also known as Bai Tou Weng) is one of its main herbal sources. Studies have shown that the main active ingredients in Pulsatilla plants are saponins, such as Pulsatilloside A, Pulchinenoside C (PSC or Anemoside B4, AB4), Pulsatilla saponin D (PSD or SB365) and Pulsatilloside E (PSE). The article “TRITERPENOIDS FROMPULSATILLA CHINENSIS” by WEN-Cai Ye et al. extracted Pulsatilloside A from Pulsatilla chinensis for the first time.

[0003] There is no literature report on the use of Pulsatilloside A for anti-radiation.

[0005] The present invention provides a new use of Pulsatilloside A, in particular, its use in anti-radiation.

[0006] The invention provides use of Pulsatilloside A in preparing a medicine with anti-radiation effect.

[0007] The present invention provides the use of Pulsatilloside A in preparing a health product having an auxiliary protective effect against ionizing radiation hazards. The radiation includes ionizing radiation and non-ionizing radiation.

[0008] The medicine is a medicine for increasing white blood cells, red blood cells, platelets and lymphocytes.

[0009] The drug is a drug that enhances serum CAT and SOD activities, increases serum GSH content, and reduces serum TNF-α content;

[0010] The medicine is a medicine for increasing the DNA content of bone marrow cells and increasing the thymus index and spleen index.

[0011] Wherein, the pharmaceutical preparation is an oral preparation or an external preparation.

[0012] Compared with other anti-radiation drugs, the Pulsatilloside A of the present invention has less toxicity and better anti-radiation effect. DETAILED DESCRIPTION

[0013] The Pulsatilloside A used in the present invention is obtained by alkali hydrolysis and then acid hydrolysis of Pulsatilloside B4, followed by high pressure preparation, separation and purification.

[0014] Test Example 1 Test on the Anti-radiation Effect of Pulsatilloside A of the Present Invention

[0015] The radiation damage model was replicated using X-rays as the radiation source, and the anti-radiation damage effect of Pulsatilloside A was evaluated by peripheral blood count, serum catalase (CAT) activity, serum superoxide dismutase (SOD) activity, serum reduced glutathione (GSH) content, serum tumor necrosis factor-α (TNF-α), bone marrow cell DNA content, spleen index and thymus index.

[0016] 1. Replication of radiation injury rat model

[0017] X-rays were used as the radiation source, with a skin-source distance of 1 m and an irradiation field of 3 × 4 m. 2 The whole body was irradiated uniformly with 10 Gy at one time, the absorbed dose rate was 2.5 Gy / min, and the irradiation time was 4 minutes.

[0018] 2. Experimental groups and drug administration methods

[0019] Fifty SPF SD healthy male rats, weighing 200±20g, were housed in the laboratory for one week and randomly divided into a blank group, a model group, a low-dose PulsatillosideA group, a medium-dose PulsatillosideA group, and a high-dose PulsatillosideA group, with 10 rats in each group. The PulsatillosideA group and the model group were used to replicate the radiation injury rat model according to the above method. The blank group was sham-irradiated, and the whole body was uniformly irradiated with 0Gy at a time, with an absorbed dose rate of 0Gy / min. After modeling, the low-dose group of Pulsatilloside A was gavaged with a 1.0 mg / ml solution diluted with 2.0% Tween water, the medium-dose group of Pulsatilloside A was gavaged with a 2.0% Tween water solution diluted with 2.0% Tween water to a 2.0 mg / ml solution, and the high-dose group of Pulsatilloside A was gavaged with a 4.0 mg / ml solution diluted with 2.0% Tween water. The blank group and the model group were gavaged with 2.0% Tween water at a dose of 10.0 ml / kg, once a day, for 30 consecutive days.

[0020] 3. Evaluation indicators

[0021] Blood was collected from the tail vein on the 15th and 30th day after administration, and the peripheral blood count was detected by an automatic blood cell counter. After the last administration, the rats were fasted but not watered for 12 hours, weighed, and the body weight was recorded. The rats were anesthetized, and blood was collected from the abdominal aorta and killed. The Elisa method was used to determine the activity of serum catalase (CAT), serum superoxide dismutase (SOD), serum reduced glutathione (GSH), and serum tumor necrosis factor-α (TNF-α). The femur of one side of the rat was peeled off, and the two ends of the femur were cut short with surgical scissors to expose the bone marrow cavity. 10mL, 5mmol·L -1 The bone marrow was washed with calcium chloride into a centrifuge tube, placed in a 4°C refrigerator for 30 min, centrifuged at 3000 r / min for 10 min, the supernatant was discarded, and the precipitate was collected. -1 Dissolve the mixture in 5 mL of perchloric acid, heat at 90°C for 15 min, cool in ice water for 5 min, centrifuge at 2500 r / min for 10 min at 4°C, take the supernatant, measure the absorbance (A) at 268 nm, and use the A268 value as the representative value of DNA content. Take the spleen and thymus, and calculate the spleen index and thymus index: spleen index = spleen weight (mg) / body weight (g); thymus index = thymus weight (mg) / body weight (g).

[0022] 4. Test results

[0023] 4.1 Effect of Pulsatilloside A on the blood count of radiation-damaged rats

[0024] Compared with the normal group, the number of white blood cells, red blood cells, platelets and lymphocytes in the peripheral blood of the rats after radiation was reduced; compared with the model group, the Pulsatilloside A group could significantly increase the number of white blood cells, red blood cells, platelets and lymphocytes in the peripheral blood of the rats with radiation damage (p < 0.05). The effect became more obvious with the extension of the administration time, and the high dose of Pulsatilloside A had the best effect. The results are shown in Table 1.

[0025] Table 1 Effects of Pulsatilloside A on blood counts of radiation-damaged rats

[0026]

[0027] Compared with the model group, * P<0.05, ** P<0.01; compared with the blank group, # P<0.05, ## P<0.01; compared with the medium dose group, the low dose group & P<0.05, && P<0.01; compared with the high-dose group, the low-dose group ￥ P<0.05, ￥￥ P<0.01; compared with the high-dose group, the medium-dose group $ P<0.05, $$ P<0.01. 4.2 Effect of Pulsatilloside A on serum CAT, SOD, GSH and TNF-α in rats with radiation injury

[0028] Compared with the normal group, the serum CAT activity and SOD activity of the model group decreased, the GSH content decreased, and the TNF-α content increased. Compared with the model group, Pulsatilloside A can significantly increase the serum CAT activity and SOD activity of radiation-damaged rats, increase the GSH content, and reduce the TNF-α content (p < 0.05), and the high-dose Pulsatilloside A group has the best effect. The results are shown in Table 2.

[0029] Table 2 Effects of Pulsatilloside A on serum CAT, SOD, GSH and TNF-α in rats with radiation injury

[0030]

[0031]

[0032] Compared with the model group, * P<0.05, **P<0.01; compared with the blank group, # P<0.05, ## P<0.01; compared with the medium dose group, the low dose group & P<0.05, && P<0.01; compared with the high-dose group, the low-dose group ￥ P<0.05, ￥￥ P<0.01; compared with the high-dose group, the medium-dose group $ P<0.05, $$ P<0.01.

[0033] Effects of Pulsatilloside A on DNA content of bone marrow cells, thymus and spleen indexes in radiation-damaged rats

[0034] Compared with the normal group, the DNA content of bone marrow cells, thymus index and spleen index of rats in the model group were reduced. Compared with the model group, Pulsatilloside A could significantly increase the DNA content of bone marrow cells, thymus index and spleen index of rats with radiation damage (p < 0.05), and the high-dose Pulsatilloside A group had the best effect. The results are shown in Table 3.

[0035] Table 3 Effects of Pulsatilloside A on DNA content, thymus index and spleen index of bone marrow cells in radiation-damaged rats

[0036]

[0037] Compared with the model group, * P<0.05, ** P<0.01; compared with the blank group, # P<0.05, ## P<0.01; compared with the medium dose group, the low dose group & P<0.05, && P<0.01; compared with the high-dose group, the low-dose group ￥ P<0.05, ￥￥ P<0.01; compared with the high-dose group, the medium-dose group $ P<0.05, $$ P<0.01.

[0038] The radiation damage model was replicated with X-ray as the radiation source, and the effect of the compound essential oil on radiation damage was evaluated by peripheral blood count, serum catalase (CAT) activity, serum superoxide dismutase (SOD) activity, serum reduced glutathione (GSH) content, serum tumor necrosis factor-α (TNF-α), bone marrow cell DNA content, spleen index and thymus index. It showed that Pulsatilloside A could improve the blood count of rats with X-ray radiation damage, and administration for 15d and 30d could significantly increase white blood cells, red blood cells, platelets and lymphocytes; enhance serum CAT and SOD activities, increase serum GSH content, and reduce serum TNF-α content; increase bone marrow cell DNA content and increase thymus index and spleen index. Pulsatilloside A can exert its anti-radiation effect through multiple pathways such as anti-oxidation, anti-inflammation, anti-tumor, immune enhancement, and bone marrow hematopoietic function.

Claims

1. Use of Pulsatilloside A in the preparation of drugs with anti-radiation effect.

2. Use of Pulsatilloside A in the preparation of a health product having an auxiliary protective effect against ionizing radiation hazards.

3. The use according to claim 1 or 2, characterized in that: The radiation includes ionizing radiation and non-ionizing radiation.

4. The use according to claim 1, characterized in that: The medicine is a medicine for increasing white blood cells, red blood cells, platelets and lymphocytes.

5. The use according to claim 1, characterized in that: The medicine is a medicine for enhancing the activities of serum CAT and SOD, increasing the content of serum GSH and reducing the content of serum TNF-α.

6. The use according to claim 1, characterized in that: The medicine is a medicine for increasing the DNA content of bone marrow cells and increasing the thymus index and spleen index.

7. The use according to any one of claims 1 to 3, characterized in that: The pharmaceutical preparation is an oral preparation or an external preparation.

Images